安博在线客服-安博(中国)

Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)

2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY™)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Secures “Drug Manufacturing Certificate”

2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023

2023-06-12
安博在线客服用于治疗晚期三阴性乳腺癌的创新药物BH009获批开展II期临床试验

2023-04-10
安博在线客服BH009新药项目在晚期头颈部鳞癌和卵巢癌患者中的I期临床试验完成首例患者给药

2023-03-09

中欧官方网站 | 星空网页版登录入口_星空（中国） | XINGKONG.COM | 拼搏平台 | 开云手机站·官方版在线 | 拼搏 | 中欧手机版app | 安博在线客服 | 开云在线登陆入口_开云（中国） |